February 04, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Wednesday, February 04, 2026.
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their meeting held on today i.e. Wednesday, February 04, 2026 at the Registered Office of the Company ***inter-alia*** has, considered and approved the following: -

1. Un-Audited Financial Results of the Company for the Third Quarter and Nine months ended December 31, 2025, along with the Auditors' Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.

2. Re-appointment of Mr Dakshesh Shah (DIN: 00561666) as Managing Director of the Company w.e.f 30/12/2025 to 30/12/2030 for a period of 5 years.

3. Reviewed the business of the company

The Board Meeting commenced at 03.30 p.m. and concluded at 04.00 p.m.

You are requested to take the above information on records and disseminated the same on your respective websites.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited REG.NO.: 019079

Ritu Kapoor
Director
DIN: 10334249

Disclosure pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Annexure A

Name	Mr. Dakshesh Shah
Reason for change viz., appointment, resignation, removal, death or otherwise	Re-Appointment
Date of appointment /~~cessation & term of appointment~~	30.12.2025
Brief Profile	Mr. Dakshesh Shah brings over 30 years of extensive experience in Pharmaceuticals, Infrastructure, Finance, Hospitality, Healthcare, Entertainment as well as cultural initiatives, Mr. Shah continues to shape Gujarat's business landscape with his unwavering commitment to excellence and innovation. and Business Development. Throughout his career, promotional campaigns to drive business growth and enhance brand visibility. His strategic approach, industry knowledge, and leadership abilities have consistently contributed to achieving organizational objectives and expanding market reach.
Name of the listed entities in which director holds directorship and membership of the committee, if any	N.A.
Disclosure of relationships between directors in case of appointment of a director	Not Applicable
Affirmation that the Director being appointed is not debarred from the holding the Office of Director by virtue of any order of SEBI or any other such Authority.	Mr Dakshesh Shah is not debarred from the holding the office of Director by virtue of any order of SEBI or any other such Authority. Nomination and Remunerations Committee and the Board of Director of the Company has also confirmed the same.

SHUKRA PHARMACEUTICALS LTD.

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER, 2025

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Amount in Lakhs

Sr. No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	**Income from Operations**						
	Revenue from Operations	3,913.48	587.74	1,058.43	5,040.33	1,931.75	3,258.73
	Other Income	81.54	171.26	100.64	363.76	274.14	420.67
	Total Income from Operations	**3,995.01**	**759.00**	**1,159.07**	**5,404.09**	**2,205.90**	**3,679.39**
2	**Expenses**						
	(a) Cost of materials consumed	320.04	1,080.81	377.92	1,276.00	615.26	1,174.55
	(b) Purchase of Stock-in Trade	-	-	-	-	86.28	-
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	393.34	-880.33	17.50	-285.12	-66.63	-363.38
	(d) Employee Benefit Expenses	264.72	219.33	154.82	666.54	435.99	611.01
	(e) Finance Cost	28.17	28.50	15.13	83.48	32.41	59.49
	(f) Depreciation & Amortisation Expenses	83.87	80.92	69.78	243.52	206.10	300.49
	(g) Other Expenses	221.74	209.93	114.44	579.14	319.83	563.57
	Total Expenses	**1,311.87**	**739.16**	**749.58**	**2,563.56**	**1,629.25**	**2,345.73**
3	**Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)**	**2,683.15**	**19.84**	**409.49**	**2,840.54**	**576.65**	**1,333.66**
4	**Exceptional Items**	-	-	-	-	-	-
5	**Profit / (Loss) before Extra ordinary items and Tax (3-4)**	**2,683.15**	**19.84**	**409.49**	**2,840.54**	**576.65**	**1,333.66**
6	**Extra ordinary items**	-	-	-	-	-	-
7	**Net Profit / (Loss) from Ordinary Activities before Tax (5-6)**	**2,683.15**	**19.84**	**409.49**	**2,840.54**	**576.65**	**1,333.66**
8	**Tax Expenses**						
	I. Current Tax	249.05	-	88.88	289.64	144.27	362.36
	II. Deferred Tax	235.48	-217.96	4.17	11.28	13.51	13.78
	II. Tax of Earlier Year	162.15		-	162.15	-	-
	IV. MAT Credit Entitlement	-		-		-	
9	**Net Profit / (Loss) for the Period (7-8)**	**2,036.46**	**237.81**	**316.44**	**2,377.46**	**418.87**	**957.51**
10	**Other Comprehensive Income (net of Tax)**						
	Remeasurement of defined benefit plans	-	-	-	-	-	1.08
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	**Total Comprehensive Income for the period (9+10)**	**2,036.46**	**237.81**	**316.44**	**2,377.46**	**418.87**	**958.59**
12	**Paid up Equity Share Capital**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**
13	**Face Value of Equity Shares**	**1.00**	**1.00**	**10.00**	**1.00**	**10.00**	**1.00**
14	**Earnings per Share (of Re. 10/- each) :**						
	(a) Basic-Rs	0.47	0.05	0.72	0.54	0.96	0.22
	(b) Diluted-Rs	0.47	0.05	0.72	0.54	0.96	0.22

NOTES:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 04th February, 2026.The statutory auditors have carried out review of the results for the quarter ended on 31st December, 2025 and have expressed an unqualified audit opinion.
2. The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
3. The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the quarter ended 31st December, 2025, 0 complaints were received out of that 0 complaints were disposed off at the end of the quarter.
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in single segment, so above results are for single segment only.

Place: Ahmedabad
Date: 04.02.2026

Shukra Pharmaceuticals Limited REG.NO.: 019079

For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Dakshesh Shah
Director
DIN:00561666

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com Website : www.shukrapharmaceuticals .com

INDEPENDENT AUDITOR'S REVIEW REPORT on the Quarterly and Nine-Month Unaudited Standalone Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED,
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter and nine months ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").


2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Shah Sanghvi & Associates
[Firm Registration No.140107W]
Chartered Accountants





Ravi Shah
Partner
Mem no: 149091

Date : 04/02/2026
UDIN :26149091PPDBKR2292

SHUKRA PHARMACEUTICALS LTD.

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER, 2025

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Amount in Lakhs

Sr. No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		31.12.2025 (Unaudited)	30.09.2025 (Unaudited)	31.12.2024 (Unaudited)	31.12.2025 (Unaudited)	31.12.2024 (Unaudited)	31.03.2025 (Audited)
1	**Income from Operations**						
	Revenue from Operations	3,913.48	587.74	1,058.43	5,040.33	1,931.75	3,258.73
	Other Income	81.54	171.26	100.64	363.76	274.14	420.67
	Total Income from Operations	**3,995.01**	**759.00**	**1,159.07**	**5,404.09**	**2,205.90**	**3,679.39**
2	**Expenses**						
	(a) Cost of materials consumed	320.04	1,080.81	377.92	1,276.00	615.26	1,174.55
	(b) Purchase of Stock-in Trade	-	-	-	-	86.28	-
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	393.34	-880.33	17.50	-285.12	-66.63	-363.38
	(d) Employee Benefit Expenses	264.72	219.33	154.82	666.54	435.99	611.01
	(e) Finance Cost	28.17	28.50	15.13	83.48	32.41	59.49
	(f) Depreciation & Amortisation Expenses	83.87	80.92	69.78	243.52	206.10	300.49
	(g) Other Expenses	221.74	209.93	114.44	579.14	319.83	563.57
	Total Expenses	**1,311.87**	**739.16**	**749.58**	**2,563.56**	**1,629.25**	**2,345.73**
3	**Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)**	**2,683.15**	**19.84**	**409.48**	**2,840.54**	**576.65**	**1,333.66**
4	**Exceptional Items**	-	-	-	-	-	-
5	**Profit / (Loss) before Extra ordinary items and Tax (3-4)**	**2,683.15**	**19.84**	**409.48**	**2,840.54**	**576.65**	**1,333.66**
6	**Extra ordinary items**	-	-	-	-	-	-
7	**Net Profit / (Loss) from Ordinary Activities before Tax (5-6)**	**2,683.15**	**19.84**	**409.48**	**2,840.54**	**576.65**	**1,333.66**
8	**Tax Expenses**						
	I. Current Tax	249.05	-	88.88	289.64	144.27	362.36
	II. Deferred Tax	235.48	-217.96	4.17	11.28	13.51	13.78
	II. Tax of Earlier Year	162.15		-	162.15	-	-
	IV. MAT Credit Entitlement	-		-		-	
9	**Net Profit / (Loss) for the Period (7-8)**	**2,036.46**	**237.81**	**316.44**	**2,377.46**	**418.87**	**957.51**
10	**Other Comprehensive Income (net of Tax)**						
	Remeasurement of defined benefit plans	-	-	-	-	-	1.08
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	**Total Comprehensive Income for the period (9+1**	**2,036.46**	**237.81**	**316.44**	**2,377.46**	**418.87**	**958.59**
12	**Paid up Equity Share Capital**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**
13	**Face Value of Equity Shares**	**1.00**	**1.00**	**10.00**	**1.00**	**10.00**	**1.00**
14	**Earnings per Share (of Re. 10/- each) :**						
	(a) Basic-Rs	0.47	0.05	0.72	0.54	0.96	0.22
	(b) Diluted-Rs	0.47	0.05	0.72	0.54	0.96	0.22

NOTES:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 4th February, 2026.The statutory auditors have carried out review of the results for the quarter ended on 31st December, 2025 and have expressed an unqualified audit
2. The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
3. The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the quarter ended 31st December, 2025, 0 complaints were received out of that 0 complaints were disposed off at the end of the quarter.
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in single segment, so above results are for single segment only.

Place: Ahmedabad
Date: 04.02.2026

Shukra Pharmaceuticals Limited REG.NO.: 019079

For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Dakshesh Shah
Director
DIN:00561666

CIN : L24231GJ1993PLC019079

INDEPENDENT AUDITOR'S REVIEW REPORT on the Quarterly and Nine-Month Unaudited Consolidated Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED,
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter and nine months ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:

    1) Shukra Robotics Private Limited
    2) Shukra Woundcare Private Limited
    3) Shukra Diabetes Technologies Private Limited
    4) Shukra Healthtech Private Limited



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Emphasis of Matter – No Such thing requires to be mentioned hence our conclusion is not modified in respect of this matter.

7. The Consolidated Unaudited Financial Results includes the Interim Financial Results of five subsidiary, which have been reviewed by us, whose Interim Financial results reflect total revenue of NIL and total net profit / (loss) after tax of Rs. NIL and total comprehensive income / loss of Rs. NIL for the quarter and half year ended December 31, 2025, as considered in the Consolidated Unaudited Financial Results.

For, Shah Sanghvi & Associates
[Firm Registration No.140107W]
Chartered Accountants

Ravi Shah
Partner
Mem no: 149091

Date : 04/02/2026
UDIN : 26149091AGGBPL1058